Why the study?
What are the risk factors for the development of auditory toxicity in patients receiving aminoglycosides?
Population
135 patients receiving aminoglycosides enrolled in three prospective, randomized, double-blind clinical trials
Design
Cohort, Original trials were randomized, Original trials were double-blind
Authors
Loading...
Patients with prolonged aminoglycoside therapy or identified factors warrant closer monitoring; hypothesis-generating and requires prospective validation.
What are the risk factors for the development of auditory toxicity in patients receiving aminoglycosides?
Longer therapy duration, bacteremia, higher temperature, liver dysfunction, and BUN:creatinine ratio are significant risk factors for aminoglycoside-induced auditory toxicity.
Moore et al. (1984) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: